FXR/TGR5 dual agonist prevents progression of nephropathy in diabetes and obesity

Xiaoxin X. Wang, Dong Wang, Yuhuan Luo, Komuraiah Myakala, Evgenia Dobrinskikh, Avi Z. Rosenberg, Jonathan Levi, Jeffrey B. Kopp, Amanda Field, Ashley Hill, Scott Lucia, Liru Qiu, Tao Jiang, Yingqiong Peng, David Orlicky, Gabriel Garcia, Michal Herman-Edelstein, Vivette D’Agati, Kammi Henriksen, Luciano AdoriniMark Pruzanski, Cen Xie, Kristopher W. Krausz, Frank J. Gonzalez, Suman Ranjit, Alexander Dvornikov, Enrico Gratton, Moshe Levi

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Bile acids are ligands for the nuclear hormone receptor farnesoid X receptor (FXR) and the G protein–coupled receptor TGR5. We have shown that FXR and TGR5 have renoprotective roles in diabetes- and obesity-related kidney disease. Here, we determined whether these effects are mediated through differential or synergistic signaling pathways. We administered the FXR/TGR5 dual agonist INT-767 to DBA/2J mice with streptozotocin-induced diabetes, db/db mice with type 2 diabetes, and C57BL/6J mice with high-fat diet-induced obesity. We also examined the individual effects of the selective FXR agonist obeticholic acid (OCA) and the TGR5 agonist INT-777 in diabetic mice. The FXR agonist OCA and the TGR5 agonist INT-777 modulated distinct renal signaling pathways involved in the pathogenesis and treatment of diabetic nephropathy. Treatment of diabetic DBA/2J and db/db mice with the dual FXR/TGR5 agonist INT-767 improved proteinuria and prevented podocyte injury, mesangial expansion, and tubulointerstitial fibrosis. INT-767 exerted coordinated effects on multiple pathways, including stimulation of a signaling cascade involving AMP-activated protein kinase, sirtuin 1, PGC-1a, sirtuin 3, estrogen-related receptor-a, and Nrf-1; inhibition of endoplasmic reticulum stress; and inhibition of enhanced renal fatty acid and cholesterol metabolism. Additionally, in mice with diet-induced obesity, INT-767 prevented mitochondrial dysfunction and oxidative stress determined by fluorescence lifetime imaging of NADH and kidney fibrosis determined by second harmonic imaging microscopy. These results identify the renal signaling pathways regulated by FXR and TGR5, which may be promising targets for the treatment of nephropathy in diabetes and obesity.

Original languageEnglish (US)
Pages (from-to)118-137
Number of pages20
JournalJournal of the American Society of Nephrology
Issue number1
StatePublished - Jan 2018

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'FXR/TGR5 dual agonist prevents progression of nephropathy in diabetes and obesity'. Together they form a unique fingerprint.

Cite this